CN104193644A - 甲氧萘环的丁二酸酰胺衍生物、其制备方法及用途 - Google Patents
甲氧萘环的丁二酸酰胺衍生物、其制备方法及用途 Download PDFInfo
- Publication number
- CN104193644A CN104193644A CN201410501866.0A CN201410501866A CN104193644A CN 104193644 A CN104193644 A CN 104193644A CN 201410501866 A CN201410501866 A CN 201410501866A CN 104193644 A CN104193644 A CN 104193644A
- Authority
- CN
- China
- Prior art keywords
- compound
- general formula
- applications
- preparation methods
- present
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 10
- NQMUGNMMFTYOHK-UHFFFAOYSA-N 1-methoxynaphthalene Chemical group C1=CC=C2C(OC)=CC=CC2=C1 NQMUGNMMFTYOHK-UHFFFAOYSA-N 0.000 title abstract description 5
- KZNICNPSHKQLFF-UHFFFAOYSA-N succinimide Chemical class O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 title abstract 2
- 229940053198 antiepileptics succinimide derivative Drugs 0.000 title 1
- 239000003814 drug Substances 0.000 claims abstract description 12
- 201000005569 Gout Diseases 0.000 claims abstract description 11
- 201000001431 Hyperuricemia Diseases 0.000 claims abstract description 8
- 150000001875 compounds Chemical class 0.000 claims description 41
- 239000003795 chemical substances by application Substances 0.000 claims description 8
- QOSSAOTZNIDXMA-UHFFFAOYSA-N N,N′-Dicyclohexylcarbodiimide Substances C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 claims description 6
- 238000009833 condensation Methods 0.000 claims description 4
- 150000002148 esters Chemical class 0.000 claims description 4
- 229940002612 prodrug Drugs 0.000 claims description 4
- 239000000651 prodrug Substances 0.000 claims description 4
- 238000000034 method Methods 0.000 claims description 3
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 claims description 2
- JDRMYOQETPMYQX-UHFFFAOYSA-M 4-methoxy-4-oxobutanoate Chemical compound COC(=O)CCC([O-])=O JDRMYOQETPMYQX-UHFFFAOYSA-M 0.000 claims description 2
- 239000007821 HATU Substances 0.000 claims description 2
- 239000012317 TBTU Substances 0.000 claims description 2
- CLZISMQKJZCZDN-UHFFFAOYSA-N [benzotriazol-1-yloxy(dimethylamino)methylidene]-dimethylazanium Chemical compound C1=CC=C2N(OC(N(C)C)=[N+](C)C)N=NC2=C1 CLZISMQKJZCZDN-UHFFFAOYSA-N 0.000 claims description 2
- 239000003513 alkali Substances 0.000 claims description 2
- JDRMYOQETPMYQX-UHFFFAOYSA-N butanedioic acid monomethyl ester Natural products COC(=O)CCC(O)=O JDRMYOQETPMYQX-UHFFFAOYSA-N 0.000 claims description 2
- 230000005494 condensation Effects 0.000 claims description 2
- 230000007062 hydrolysis Effects 0.000 claims description 2
- 238000006460 hydrolysis reaction Methods 0.000 claims description 2
- 229940079593 drug Drugs 0.000 abstract description 4
- 239000000203 mixture Substances 0.000 abstract description 2
- 229940127358 Urate Transporter 1 Inhibitors Drugs 0.000 abstract 4
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 101000821903 Homo sapiens Solute carrier family 22 member 12 Proteins 0.000 description 9
- 238000003756 stirring Methods 0.000 description 9
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 8
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 8
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 8
- 229940116269 uric acid Drugs 0.000 description 8
- 102100021495 Solute carrier family 22 member 12 Human genes 0.000 description 7
- 238000000605 extraction Methods 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 3
- SNCZNSNPXMPCGN-UHFFFAOYSA-N butanediamide Chemical class NC(=O)CCC(N)=O SNCZNSNPXMPCGN-UHFFFAOYSA-N 0.000 description 3
- 238000004440 column chromatography Methods 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 3
- 230000029142 excretion Effects 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- FGQFOYHRJSUHMR-UHFFFAOYSA-N lesinurad Chemical compound OC(=O)CSC1=NN=C(Br)N1C(C1=CC=CC=C11)=CC=C1C1CC1 FGQFOYHRJSUHMR-UHFFFAOYSA-N 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 238000000967 suction filtration Methods 0.000 description 3
- ASUMVAPLXCRBMA-UHFFFAOYSA-N (3,5-dichloro-4-hydroxyphenyl)-(2,3-dihydro-1,4-benzoxazin-4-yl)methanone Chemical compound C1=C(Cl)C(O)=C(Cl)C=C1C(=O)N1C2=CC=CC=C2OCC1 ASUMVAPLXCRBMA-UHFFFAOYSA-N 0.000 description 2
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 2
- 241001415342 Ardea Species 0.000 description 2
- 108010078791 Carrier Proteins Proteins 0.000 description 2
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 102100030935 Solute carrier family 2, facilitated glucose transporter member 9 Human genes 0.000 description 2
- 229940083914 URAT1 inhibitor Drugs 0.000 description 2
- 229960003459 allopurinol Drugs 0.000 description 2
- OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 description 2
- 229960002529 benzbromarone Drugs 0.000 description 2
- WHQCHUCQKNIQEC-UHFFFAOYSA-N benzbromarone Chemical compound CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC(Br)=C(O)C(Br)=C1 WHQCHUCQKNIQEC-UHFFFAOYSA-N 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 238000013016 damping Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 239000005457 ice water Substances 0.000 description 2
- 229960003838 lesinurad Drugs 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000002000 scavenging effect Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 108010078530 urate transporter Proteins 0.000 description 2
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 206010051779 Bone marrow toxicity Diseases 0.000 description 1
- 239000002083 C09CA01 - Losartan Substances 0.000 description 1
- KDXKERNSBIXSRK-RXMQYKEDSA-N D-lysine Chemical compound NCCCC[C@@H](N)C(O)=O KDXKERNSBIXSRK-RXMQYKEDSA-N 0.000 description 1
- 239000006145 Eagle's minimal essential medium Substances 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical class OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 108010068701 Pegloticase Proteins 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- KDCGOANMDULRCW-UHFFFAOYSA-N Purine Natural products N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 1
- 229940123769 Xanthine oxidase inhibitor Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 231100000366 bone marrow toxicity Toxicity 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229960001338 colchicine Drugs 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000002360 explosive Substances 0.000 description 1
- 229960005101 febuxostat Drugs 0.000 description 1
- BQSJTQLCZDPROO-UHFFFAOYSA-N febuxostat Chemical compound C1=C(C#N)C(OCC(C)C)=CC=C1C1=NC(C)=C(C(O)=O)S1 BQSJTQLCZDPROO-UHFFFAOYSA-N 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000304 hepatotoxicity Toxicity 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- KJJZZJSZUJXYEA-UHFFFAOYSA-N losartan Chemical compound CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C=2[N]N=NN=2)C=C1 KJJZZJSZUJXYEA-UHFFFAOYSA-N 0.000 description 1
- 229960004773 losartan Drugs 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- NAFSTSRULRIERK-UHFFFAOYSA-M monosodium urate Chemical class [Na+].N1C([O-])=NC(=O)C2=C1NC(=O)N2 NAFSTSRULRIERK-UHFFFAOYSA-M 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 229960001376 pegloticase Drugs 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 235000013926 potassium gluconate Nutrition 0.000 description 1
- ZVIWEYTXPYNLGB-UHFFFAOYSA-M potassium;4-[[2-[[5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-1,2,4-triazol-3-yl]sulfanyl]acetyl]amino]-3-chlorobenzoate Chemical compound [K+].ClC1=CC(C(=O)[O-])=CC=C1NC(=O)CSC1=NN=C(Br)N1C(C1=CC=CC=C11)=CC=C1C1CC1 ZVIWEYTXPYNLGB-UHFFFAOYSA-M 0.000 description 1
- 229960003081 probenecid Drugs 0.000 description 1
- DBABZHXKTCFAPX-UHFFFAOYSA-N probenecid Chemical compound CCCN(CCC)S(=O)(=O)C1=CC=C(C(O)=O)C=C1 DBABZHXKTCFAPX-UHFFFAOYSA-N 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 238000001525 receptor binding assay Methods 0.000 description 1
- 230000000452 restraining effect Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 229960003329 sulfinpyrazone Drugs 0.000 description 1
- MBGGBVCUIVRRBF-UHFFFAOYSA-N sulfinpyrazone Chemical compound O=C1N(C=2C=CC=CC=2)N(C=2C=CC=CC=2)C(=O)C1CCS(=O)C1=CC=CC=C1 MBGGBVCUIVRRBF-UHFFFAOYSA-N 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000003104 tissue culture media Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 239000003064 xanthine oxidase inhibitor Substances 0.000 description 1
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
Claims (6)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410501866.0A CN104193644B (zh) | 2014-09-27 | 2014-09-27 | 甲氧萘环的丁二酸酰胺衍生物、其制备方法及用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410501866.0A CN104193644B (zh) | 2014-09-27 | 2014-09-27 | 甲氧萘环的丁二酸酰胺衍生物、其制备方法及用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN104193644A true CN104193644A (zh) | 2014-12-10 |
CN104193644B CN104193644B (zh) | 2015-12-02 |
Family
ID=52079056
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201410501866.0A Expired - Fee Related CN104193644B (zh) | 2014-09-27 | 2014-09-27 | 甲氧萘环的丁二酸酰胺衍生物、其制备方法及用途 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN104193644B (zh) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN87107217A (zh) * | 1986-10-31 | 1988-05-11 | 大塚制药株式会社 | 吡唑并三嗪化合物 |
CN101010300A (zh) * | 2004-08-27 | 2007-08-01 | 安斯泰来制药株式会社 | 2-苯基吡啶衍生物 |
CN101282934A (zh) * | 2005-10-07 | 2008-10-08 | 安斯泰来制药株式会社 | 三芳基羧酸衍生物 |
WO2011082268A2 (en) * | 2009-12-30 | 2011-07-07 | Arqule Inc. | Substituted naphthalenyl-pyrimidine compounds |
WO2012106509A1 (en) * | 2011-02-02 | 2012-08-09 | The Trustees Of Princeton University | Sirtuin modulators as virus production modulators |
-
2014
- 2014-09-27 CN CN201410501866.0A patent/CN104193644B/zh not_active Expired - Fee Related
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN87107217A (zh) * | 1986-10-31 | 1988-05-11 | 大塚制药株式会社 | 吡唑并三嗪化合物 |
CN101010300A (zh) * | 2004-08-27 | 2007-08-01 | 安斯泰来制药株式会社 | 2-苯基吡啶衍生物 |
CN101282934A (zh) * | 2005-10-07 | 2008-10-08 | 安斯泰来制药株式会社 | 三芳基羧酸衍生物 |
WO2011082268A2 (en) * | 2009-12-30 | 2011-07-07 | Arqule Inc. | Substituted naphthalenyl-pyrimidine compounds |
WO2012106509A1 (en) * | 2011-02-02 | 2012-08-09 | The Trustees Of Princeton University | Sirtuin modulators as virus production modulators |
Also Published As
Publication number | Publication date |
---|---|
CN104193644B (zh) | 2015-12-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104311442B (zh) | 卤代萘环的丁二酸酰胺衍生物、其制备方法及用途 | |
CN104292123B (zh) | 苯基萘环的丁二酸酰胺衍生物、其制备方法及用途 | |
CN104311441B (zh) | 一类氯代萘环的丁二酸酰胺衍生物、其制备方法及用途 | |
CN104193644A (zh) | 甲氧萘环的丁二酸酰胺衍生物、其制备方法及用途 | |
CN104311452B (zh) | 腈基萘环的丁二酸酰胺衍生物、其制备方法及用途 | |
CN104292124B (zh) | 硝基苯基取代的萘环丁二酸酰胺衍生物、其制备方法及用途 | |
CN104311444B (zh) | 硝基取代萘环的丁二酸酰胺衍生物、其制备方法及用途 | |
CN104370841B (zh) | 三氮唑亚磺酰丙二酸类化合物、其制备方法及用途 | |
CN104311443B (zh) | 一类含萘环的丁二酸酰胺衍生物、其制备方法及用途 | |
CN104311445B (zh) | 含萘环的丁二酸酰胺衍生物、其制备方法及用途 | |
CN104341364A (zh) | 三氮唑丙二酸类化合物、其制备方法及用途 | |
CN104326999B (zh) | 烷氧基取代的三氮唑亚磺酰丙二酸类化合物、其制备方法及用途 | |
CN104326997B (zh) | 烷氧基取代的三氮唑丙二酸类化合物、其制备方法及用途 | |
CN104327000B (zh) | 苯基取代的三氮唑亚磺酰丙二酸类化合物、其制备方法及用途 | |
CN104311498B (zh) | 烷氧基取代的三氮唑磺酰丙二酸类化合物、其制备方法及用途 | |
CN104341362A (zh) | 三氮唑磺酰丙二酸类化合物、其制备方法及用途 | |
CN104326998B (zh) | 苯基取代的三氮唑丙二酸类化合物、其制备方法及用途 | |
CN104370842B (zh) | 苯基取代的三氮唑磺酰丙二酸类化合物、其制备方法及用途 | |
CN104341367B (zh) | 一类四氮唑乙酸类化合物、其制备方法及用途 | |
CN104341361B (zh) | 一种腈基取代三氮唑亚磺酰丙二酸类化合物、其制备方法及用途 | |
CN104262276A (zh) | 含卤代苯的四氮唑乙酸类化合物、其制备方法及用途 | |
CN104341363B (zh) | 一种硝基取代的三氮唑磺酰丙二酸类化合物、其制备方法及用途 | |
CN104326993B (zh) | 一种硝基取代三氮唑亚磺酰丙二酸类化合物、其制备方法及用途 | |
CN104370843A (zh) | 卤代三氮唑亚磺酰丙二酸类化合物、其制备方法及用途 | |
CN104341365A (zh) | 卤代三氮唑丙二酸类化合物、其制备方法及用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20170803 Address after: 510640 Guangdong City, Tianhe District Province, No. five, road, public education building, unit 371-1, unit 2401 Patentee after: Guangdong Gaohang Intellectual Property Operation Co., Ltd. Address before: 528000 Guangdong, Foshan District, Pu Lan Road, the first floor of the first floor, No. 5, Chancheng Patentee before: Zhang Yuanqiang |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20170928 Address after: 226500, No. 6, No. 1 Chemical Avenue, Changjiang town (Rugao port area), Nantong, Jiangsu, Rugao Patentee after: Nantong Zhengda Agrochemical Co., Ltd. Address before: 510640 Guangdong City, Tianhe District Province, No. five, road, public education building, unit 371-1, unit 2401 Patentee before: Guangdong Gaohang Intellectual Property Operation Co., Ltd. |
|
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20151202 Termination date: 20200927 |